VREOF · Vireo Growth Inc.
Market Cap
$541.13M
Shares
48.06M
Volume · Oct 5
38.85K
Avg daily vol (3M)
41.48K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.34
Open$9.46
Day$9.34–9.78
52W close$9.34–21.90
Avg vol 30d59K
Short int34K · 0.1% float · 1.0d
Short vol8%
Last earningsAug 11, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
Next earnings call
Nov 10, 2026
Est · unconfirmed
· in 5 wks
filed Aug 14, 2026
call held Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$511.67M
Trailing 12 months
Net income (TTM)
−$67.11M
Trailing 12 months
Revenue growth YoY
+335.1%
Year over year
Operating margin
0.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-21.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+141.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−27%
below
Price vs 50-day avg
−14%
below
RSI (14)
34
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−26%
trailing
6-month return
−27%
trailing
YTD return
−49%
this year
Relative strength
−39%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $13 — 200d above 50d
Institutional flow
Accumulating
+1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.07% of float · ▲ +462.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Squeeze score
42
elevated · 0–100
Fundamentals
Revenue growth
+170%
Y/Y
Gross margin
47%
contracting
EPS growth
+44%
Y/Y
Free cash flow
$-24.6M
Balance sheet
$42.9M
net debt
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−27%
Bearish
Price vs 50-day avg
−14%
Bearish
RSI (14)
34
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $11 › 200d $13 — 200d above 50d
Institutional flow
Accumulating
+1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.07% of float · ▲ +462.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $9
Now $9 · 0%
Range high $22
vs 200-day avg -27%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cannabis segment revenue from retail dispensaries | 88% | the three months ended June 30, 2026 filing | — |
| Cannabis segment revenue from wholesale business | 12% | the three months ended June 30, 2026 filing | — |
| Adjusted Cannabis EBITDA (non-GAAP) non-GAAP | $39.4M | Three Months Ended June 30, 2026 | — |
| Adjusted Cannabis EBITDA Margin non-GAAP | 22.4% | Three Months Ended June 30, 2026 | — |
| Adjusted Cannabis Gross Profit non-GAAP | $92.4M | Three Months Ended June 30, 2026 | — |
| Adjusted Cannabis Gross Profit Margin non-GAAP | 52.6% | Three Months Ended June 30, 2026 | — |
| Adjusted EBITDA (non-GAAP) non-GAAP | $41.5M | Three Months Ended June 30, 2026 | — |
| Adjusted EBITDA Margin non-GAAP | 19.8% | Three Months Ended June 30, 2026 | — |
| Adjusted Gross Profit non-GAAP | $98.4M | Three Months Ended June 30, 2026 | — |
| Adjusted Gross Profit Margin non-GAAP | 47% | Three Months Ended June 30, 2026 | — |
| Adjusted Non-Cannabis EBITDA (non-GAAP) non-GAAP | $2.1M | Three Months Ended June 30, 2026 | — |
| Adjusted Non-Cannabis EBITDA Margin non-GAAP | 6.3% | Three Months Ended June 30, 2026 | — |
| Adjusted Non-Cannabis Gross Profit non-GAAP | $6M | Three Months Ended June 30, 2026 | — |
| Adjusted Non-Cannabis Gross Profit Margin non-GAAP | 17.9% | Three Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VREOF
this stock
Vireo Growth Inc.
|
$541.13M | — | +170.4% | — | 0.1% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.2% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +27.1% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -12.8% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
1
- % held
- 0.0%
- Net QoQ
- +333 sh
- Top holder
- RESOURCES MANAGEMENT CORP…
Held
Float
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VREOF | -7.1% | -25.6% | -27.3% | -3.3% | -49.2% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -8.3% | -26.2% | -38.8% | -4.9% | -62.8% |